Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | VDR | P11473 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850074 | 0.87 | PPARG (0.52) | KDRFFAR1PPARGPPARAVDR | |
| SCHEMBL4845929 | 0.87 | KDR (0.52) | KDRFFAR1PPARGPPARAVDR | |
| SCHEMBL3278854 | 0.82 | MAPT (0.68) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL3281065 | 0.81 | KDR (0.76) | KDRFFAR1PPARGPPARAPPARD | |
| SCHEMBL4852529 | 0.80 | SMN1; SMN2 (0.47) | FFAR1PPARGPPARAVDRESR1 | |
| SCHEMBL4029049 | 0.80 | KDR (0.64) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL2078397 | 0.80 | KDM4E (0.52) | PPARGVDRMAPTTP53 | |
| SCHEMBL4032635 | 0.79 | FFAR1 (0.61) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL4855092 | 0.78 | PPARG (0.49) | KDRFFAR1PPARGPPARAVDR | |
| SCHEMBL12468785 | 0.78 | TP53 (0.67) | FFAR1PPARGPPARAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | KDR 2335/4885FFAR1 771/4885PPARG 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.